Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Sees Significant Growth in Short Interest

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO - Get Free Report) was the recipient of a significant increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,720,000 shares, an increase of 34.4% from the January 31st total of 1,280,000 shares. Currently, 10.1% of the shares of the company are sold short. Based on an average daily trading volume, of 192,900 shares, the short-interest ratio is currently 8.9 days.

Analysts Set New Price Targets

TELO has been the topic of several analyst reports. RODMAN&RENSHAW raised Telomir Pharmaceuticals to a "strong-buy" rating in a report on Thursday, February 20th. Rodman & Renshaw began coverage on shares of Telomir Pharmaceuticals in a research note on Friday, February 21st. They set a "buy" rating and a $15.00 price objective on the stock.

Institutional Trading of Telomir Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the company. Gotham Asset Management LLC purchased a new position in Telomir Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rhumbline Advisers lifted its position in shares of Telomir Pharmaceuticals by 105.9% during the 4th quarter. Rhumbline Advisers now owns 8,600 shares of the company's stock worth $35,000 after buying an additional 4,424 shares during the last quarter. Corebridge Financial Inc. boosted its holdings in shares of Telomir Pharmaceuticals by 273.8% in the 4th quarter. Corebridge Financial Inc. now owns 9,613 shares of the company's stock valued at $40,000 after buying an additional 7,041 shares in the last quarter. Wells Fargo & Company MN grew its position in shares of Telomir Pharmaceuticals by 458.3% in the 4th quarter. Wells Fargo & Company MN now owns 10,044 shares of the company's stock valued at $41,000 after buying an additional 8,245 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Telomir Pharmaceuticals by 279.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,699 shares of the company's stock worth $44,000 after acquiring an additional 7,879 shares in the last quarter.

Remove Ads

Telomir Pharmaceuticals Stock Up 5.9 %

Shares of NASDAQ TELO traded up $0.25 during midday trading on Friday, hitting $4.39. The stock had a trading volume of 93,399 shares, compared to its average volume of 122,095. Telomir Pharmaceuticals has a 1 year low of $3.11 and a 1 year high of $9.39. The company has a market capitalization of $130.51 million and a PE ratio of -7.57. The stock has a 50 day simple moving average of $4.40 and a 200-day simple moving average of $4.85.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last issued its earnings results on Tuesday, February 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.05). As a group, analysts expect that Telomir Pharmaceuticals will post -0.4 earnings per share for the current fiscal year.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.